TCRX
TScan Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TCRX
Tscan Therapeutics, Inc.
A preclinical-stage biopharmaceutical company that developing T cell receptor engineered T cell therapies for the treatment of cancer
830 Winter Street, Waltham, Massachusetts 02451
--
TScan Therapeutics, Inc., was incorporated in Delaware on April 17, 2018. The company is a preclinical stage biopharmaceutical company focused on developing powerful T cell receptor engineered T cells or TCR-T therapies for the treatment of cancer patients.
Company Financials
EPS
TCRX has released its 2025 Q3 earnings. EPS was reported at -0.28, versus the expected -0.33, beating expectations. The chart below visualizes how TCRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TCRX has released its 2025 Q3 earnings report, with revenue of 2.51M, reflecting a YoY change of 139.37%, and net profit of -35.71M, showing a YoY change of -19.48%. The Sankey diagram below clearly presents TCRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
